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Among matrix metalloproteinases (MMPs), MMP-19 displays unique structural 
features and tissue distribution. In contrast to most MMPs, MMP-19 is expressed in 
normal human epidermis and downregulated during malignant transformation and 
dedifferentiation. The contribution of MMP-19 during tumor angiogenesis is presently 
unknown. In an attempt to give new insights into MMP-19 in vivo functions, angiogenic 
response of mutant mice lacking Mmp-19 was analysed after transplantation of murine 
malignant PDVA keratinocytes and after injection of matrigel supplemented with b-
FGF. In situ hybridization and immunohistochemical analysis revealed that MMP-19 is 
produced by host mesenchymal cells, but not by endothelial capillary cells or CD11b-
positive inflammatory cells. Based on a new computer-assisted method of 
quantification, we provide evidence that host Mmp-19 deficiency was associated with 
an increased early angiogenic response. In addition, increased tumor invasion was 
observed in Mmp-19-/- mice. We conclude that, in contrast to most MMPs which 
promote tumor progression, Mmp-19 is a negative regulator of early steps of tumor 
angiogenesis and invasion. These data highlight the requirement to understand the 





Matrix metalloproteinases (MMPs) are a family of structurally related zinc-
dependent neutral endopeptidases that play major roles in tissue remodeling occurring 
in a variety of physiological processes such as embryonic development, angiogenesis 
and wound healing (1, 2). They are main effectors of pathological extracellular matrix 
destruction in many diseases such as arthritis, atherosclerosis, age-related macular 
degeneration, tumor invasion and metastasis (3-7). MMPs contribute to the fine tuning 
of  diverse biological processes through limited proteolysis of specific targets including 
not only matrix components, but also growth factors, chemokines/cytokines and cell 
surface receptors (8-11). More than 20 different human MMPs have been identified (12) 
and classified into different subfamilies according to their primary structure, domain 
organization, cellular localization and substrate specificity (11, 13, 14). Produced as 
latent forms, they are either secreted in the extracellular medium or associated to the 
cell membrane (Membrane-type MMPs or MT-MMPs) (7, 11, 14).  
Among MMPs, MMP-19 displays unique structural features and tissue distribution. 
Human MMP-19 cDNA was initially cloned from liver and mammary gland and was 
also identified as an autoantigen in inflamed rheumatoid synovium (15, 16). MMP-19 
presents the typical domain organization of soluble MMPs, including a signal sequence, 
a propeptide maintaining enzyme latency, a catalytic domain with the typical zinc 
binding motif, a linker region, and a C-terminal fragment with sequence similarity to 
hemopexin (15). However, MMP-19 displays several structural features distinctive of 
the diverse MMP subfamilies including (i) an unique insertion of glutamic acid residues 
within the linker region, (ii) an unusual latency motif in propeptide domain, (iii) an 




sequence similarity to equivalent regions in other human MMPs (15, 17, 18). The 
catalytic domain of MMP-19 is capable of degrading components of basement 
membrane (laminin, type IV collagen, nidogen), connective tissue (fibronectin, type I 
gelatine) and cartilage (cartilage oligomeric matrix protein and aggrecan), but does not 
degrade triple-helical type I collagen (19, 20). In contrast to most other MMPs, MMP-
19 is expressed in human mammary or skin epithelial cells under normal quiescent 
conditions and down regulated in invasive carcinomas (21-23). 
Evidence for MMP-19 involvement in tissue remodeling events such as those 
occurring during adipogenesis and tumor progression have been provided by the recent 
generation of Mmp-19-deficient mice (24). Although lack of Mmp-19 did not affect 
mice viability, fertility and development, it led to a diet-induced obesity and a decreased 
susceptibility to skin tumors induced by chemical carcinogens. A role of MMP-19 
during angiogenesis is suggested by its expression in endothelial cells of synovial 
capillaries following injury and inflammation (3, 25). However, the ex vivo sprouting of 
endothelial cells from aortic rings was not affected by Mmp-19 deficiency (24). 
Therefore, the contribution of MMP-19 during angiogenic processes remains 
controversial. In order to give new insights into Mmp-19 functions in vivo, the 
angiogenic response of mutant mice lacking Mmp-19 was analysed after transplantation 
of malignant murine PDVA keratinocytes and after injection of matrigel supplemented 
with b-FGF. In contrast to other single or double MMP-deficient mice studied until 





Materials and Methods 
Mmp-19–null mice. Mice genetically deficient in Mmp-19 (Mmp-19-/-) were 
generated by replacing a portion of 1kb of the promoter and exons 1 and 2 of the gene 
with a phosphoglycerate kinase-neomycin fusion gene and by homologous 
recombination (24). Homozygous Mmp-19 (Mmp-19-/-) mice and their corresponding 
WT (Mmp-19+/+) were littermates deriving from interbreeding of heterozygotes with a 
mixed background of C57Bl6/129Ola. When applying the transplantation chamber 
assay to mice with different genetic background, we previously demonstrated that the 
extent of tumor invasion and vascularization was similar in all WT mice, independently 
to the number of backcrosses in C57Bl6 mice (26). Mice experimentation was done in 
accordance to guidelines of the University of Liège regarding the care and use of 
laboratory animals. 
Transplantation assay in mice. PDVA cells were generated by in vitro carcinogen 
treatment (DMA) of cultured keratinocytes issued from B10LP mice (27). PDVA cells 
were grown in modified Eagle’s minimal essential medium containing a 4-fold 
concentration of amino acids and vitamins (Gibco Laboratories, Grant Island, NY), 10% 
fetal calf serum (Gibco) and antibiotics in a humidified incubator at 37 °C, 5% CO2.  
Cells (2 x 105) were seeded on a collagen gel (4 mg/mL of type I collagen isolated from 
rat tail tendons) inserted in Teflon rings (Renner GmbH, Dannstadt, Germany). After 
24h of culture, cell-coated collagen gels were covered with a silicone transplantation 
chamber (Renner GmbH) and implanted in toto onto dorsal muscle fascia of 6-8 weeks 
old mice according to the procedure previously described (28, 29).  At different time 
points, tumor transplants were resected, embedded in Tissue Tek (Miles Laboratories 




prior to sacrifice, mice were intraperitonally injected with 200 µl of BrdU/BrdC (65 
µM, Acros Organics, Geel, Belgium). Each experimental group contained at least 6 
animals. Tumor angiogenesis and invasion in Mmp-19-/- and WT mice were evaluated 
in three independent sets of experiment. 
Histological analysis. Cryostat sections were fixed in acetone at –20°C and in 
80% methanol at 4°C. For immunofluorescence labeling, the following antibodies were 
used: anti-type IV collagen Ab (rabbit polyclonal Ab; diluted 1/100), anti-keratin Ab 
(polyclonal guinea pig Ab; diluted 1/20, Sigma-Aldrich, St Louis, MO), anti-BrdU-
FITC (monoclonal mouse, diluted 1/3.5, Becton Dickinson, San Diego, CA), anti-hinge 
region of MMP-19 (rabbit anti-human, diluted 1/20, Sigma-Aldrich; rabbit anti-human, 
diluted 1/500, Abcam, Cambridge, MA), anti- MMP-19 prodomain  (rabbit anti-human, 
diluted 1/500, Abcam), anti-CD11b/TRITC (rat anti-mouse, diluted 1/50, Pharmingen, 
San Diego, CA), anti α-smooth muscle actin/FITC (α-SMA) (monoclonal mouse 
antibody, diluted 1/200, Sigma-Aldrich). When double immunofluorescence-labelings 
were performed, after an incubation for 1 h with primary antibodies, sections were 
washed with phosphate buffered saline (PBS) and then incubated for 30 min with 
fluorescein-isothiocyanate (FITC)- or tetramethyl-rhodamine isothiocyanate (TRITC)- 
conjugated appropriate secondary antibodies: swine anti-rabbit (diluted 1/40, Dako, 
Glostrup, Denmark,), mouse anti-guinea pig (diluted 1/40, Sigma-Aldrich) or goat anti-
rat (diluted 1/100, Molecular Probes, Carlsbad, CA). After 3 washes in PBS, coverslips 
were mounted with Aqua Polymount (Polysciences, Warrington, FL) and specific 
labeling was observed using an inverted microscope equipped with epifluorescence 
optics. Sections were counterstained in blue with bisbenzimide. At all times after 
grafting, collagen type IV labelings were codistributed with endothelial cells recognized 




Apoptosis was studied by terminal deoxynucleotidyl transferase (TDT)-mediated 
deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL). Cryostat sections fixed 
in 4% paraformaldehyde for 20 min and in methanol for 5 min were stained for 
apoptosis following manufacturer’s instructions (Roche Diagnostics, Mannheim, 
Germany). 
For quantitative measurement of proliferating cells, automatic computer-assisted 
image analysis was performed on images obtained after bisbenzimide staining and 
immunolabeling of BrdU positive cells. The ratio between the surface of bisbenzimide 
staining and the surface of specific immunostaining was measured by using a software 
Aphelion 3.2 from Adsis. 
In situ hybridization: Either sense or antisense 35S-uridine triphosphate-labeled 
RNA probes were synthesized from linearized cDNA fragment (1600 bp) of mouse 
Mmp-19 gene cloned into EcoRV site of pcDNA3. Cryostat sections were hybridized 
with 35S-labeled Mmp-19 riboprobes and then exposed to photographic emulsion at 4°C 
for 6 days. Sections were developed, fixed, cleared and counterstained with 0.02% 
Toluidine Blue. Bright field and dark field images were captured with a SPOT digital 
camera. 
Scoring of tumor invasion and vascularization. For semi-quantitative analysis 
of tumor vascularization, the following scoring was used: +: vessels below the collagen 
gel or infiltrating the collagen gel without reaching the malignant epithelial layer; ++: 
blood vessels in close apposition to the epithelial layer, and +++: blood vessels 
intermingled with invasive epithelial tumor sprouts (29). 




invasion) and tumor vascularization (endothelial cell migration) were performed by 
using a computer-assisted image analysis system (Olympus Micro Image version 3.0 for 
Windows 95/NT, Olympus Optical CO. Europe GmBH) (30). Angiogenesis was 
quantified by measuring the distance (“d”) separating tumor cells from the front of 
migrating blood vessels. Therefore, the distance “d” is inversely related to the degree of 
endothelial cell migration. At least five measurements of distance (“d”) were performed 
in the central part of each tumor and the mean values are reported. 
Quantitative measurement of tumor invasion and angiogenesis by computer-
assisted image processing. For quantitative measurements, automatic computer-
assisted image analysis was performed on images obtained after double 
immunostainings of keratinocytes (in green) and vessels (in red). The software 
Aphelion 3.2 from Adsis was used on a PC. Images were first digitized in 760 x 570 
pixels with 256 grey levels. Tumor and vessels images were processed separately. For 
tumor images, histogram equalization was first performed in order to optimize the 
contrast. Then, tumor images were binarized/segmented automatically using the entropy 
of the histogram of the grey level intensities (31). For vessel images, vessels were 
binarized/segmented using an automatic threshold transformation that maximizes the 
global average contrast of edges (32). The upper boundary of the tumor was then 
automatically detected using a hit or miss transformation with an appropriate 
neighborhood configuration. A grid was constructed with the successive dilations (n=1, 
2, 3….) of this upper boundary, with a vertical line as structuring element. Tumor and 
vessel densities were determined on each interval of the grid, and the results drawn in 
function of the distance to the upper limit of the tumor. The largest distance of tumor 
invasion gives the thickness of the tumor. Quantification was performed on each mouse 




variance was performed and results were considered significantly different when the p-
value was less than 0.05.  
Matrigel plug assay. A total of 0.5 ml of Matrigel (10mg/ml) mixed with 250 ng 
of basic Fibroblast Growth Factor (bFGF) (R&D Systems, Mineapolis, MN) and 20U of 
heparin (Leo Pharma, Ballerup, Denmark) (33) was subcutaneously injected in the 
abdominal midline region of 8 week-old Mmp-19 null and wild-type mice. After 7 days, 
animals were euthanized and Matrigel implants were harvested, frozen on dry ice and 
lyophilized overnight. Dry plugs were weight and suspended in 0.4ml of 0.1% saponin 
(Calbiochem, La Jolla, CA) for 1 h at 4°C, disrupted by vigorous pipetting and 
centrifuged at 15,000g for 15 min, at 4°C to remove particulates. Concentration of 
haemoglobin in the supernatant was determined after dilution in Drapkin’s solution by 
measuring the absorbance at 560 nm (Drabkin reagent kit 525, Sigma). A standard 
curve was performed by using purified haemoglobin (Sigma). The angiogenic index 
corresponds to µg of haemoglobin per mg of Matrigel. 
Statistical analysis. All experimental data are reported as mean ± SEM, and 
statistical analysis was performed by χ2 test or Mann-Whitney test. P< 0.05 was 





Lack of Mmp-19 increased the onset of skin tumor vascularization. Malignant 
PDVA keratinocytes cultured on a collagen gel were implanted onto the dorsal muscle 
fascia of Mmp-19-/- and Mmp-19+/+ mice. In order to compare evolution of tumor 
invasion and vascularization in these genotypes, transplants were resected after 14 and 
21 days and angiogenesis was visualized after staining for collagen type IV to delineate 
capillary basement membranes (Fig. 1). Tumor grafting led to a remodeling of collagen 
matrix and a progressive infiltration by host-derived cells including endothelial cells 
and inflammatory cells. Tumor vascularization was semi-quantitatively scored 
according to the progressive migration of blood vessels towards tumor cells (Fig. 1).  At 
day 14, in Mmp-19+/+ mice, blood vessels remained below the collagen gel or started 
to infiltrate it and all samples were scored + (Fig. 1A). Tumor vascularization in Mmp-
19-/- mice was increased since 63% and 37% of transplants were scored + and ++, 
respectively (Fig. 1B) (P<0.05, χ2 test). At that time, in both genotypes, tumor layer 
appeared as an irregular stratified epithelium on top of the collagen gel (Fig. 1A). 
Vascularization of tumor transplants at day 14 was first quantified by measuring 
the distance (“d”) separating the bottom of tumor layer from the front of migrating 
blood vessels (Fig. 1D). This parameter is inversely related to the degree of endothelial 
cell migration. Compared to Mmp-19+/+ mice, vessels migrated over a higher distance 
in Mmp-19-deficient mice (Fig. 1D). Indeed, the distance separating endothelial cells to 
malignant keratinocytes was 2.5 fold reduced in Mmp-19 null mice than in their 
corresponding wild-type littermates (P=0.0062, Mann-Whitney test)(Fig. 1D).  
The observed increased blood vessel migration in Mmp-19-null mice prompted us 




blood vessels in the remodeled matrix. With this aim, an original method based on 
computer-assisted image analysis was developed (Fig. 2). The density of vessels picked 
already at a distance of around 0.25 mm from the upper boundary of tumor layer in 
Mmp-19-/- mice (Fig. 2B). In sharp contrast, the maximal density of endothelial cells 
was observed at a distance of around 0.75 mm in Mmp-19+/+ mice. A computer-
assisted method of image analysis was also set up to quantify tumor cell invasion (Fig. 
2A). At day 14 time point, no invasion was observed (Fig. 2C). This was expected since 
in the transplantation chamber assay, infiltration of vessels through the collagen gel 
towards tumor cells always precedes recognizable tumor cell invasion (34). Therefore, 
at early time point, Mmp-19-deficient mice exhibited an acceleration of blood vessel 
infiltration in the remodeled matrix. 
 
Lack of Mmp-19 increased tumor invasion 
At day 21, once blood vessels have reached tumor cell layers, malignant 
keratinocytes formed tumor sprouts that invaded downwards the remodeled host tissue 
and were intermingled with closely apposed new vessels (Fig. 1A). Such vascularization 
pattern scored +++ was observed in about 60% (10/17) of Mmp-19-/- mice and only 
22% (4/18) of Mmp-19+/+ mice (P = 0.027, χ2 test) (Fig. 1C). 
At this time point, the distance (“d”) separating tumor layer from the front of 
recruited blood vessels (Fig. 1) can not be measured since in more than 70% of tumor 
transplants, vessels have reached the tumor layer (tumors scored ++ or +++). Therefore, 
for quantitative assessment, our original method of image analysis (Fig. 2) was applied 
to determine the malignant keratinocyte density as a function of the distance to the top 
of tumor transplant (Fig. 2D). In wild-type mice, keratinocyte density decreased 




were observed at a distance higher than 0.5 mm from the top of tumor layer. In sharp 
contrast, in Mmp-19 null mice, tumor cell density decreased more slowly and numerous 
malignant keratinocytes migrated over a distance of 0.5 mm. The maximal distance of 
keratinocyte migration was 1.2 mm and 1.8 mm in Mmp-19+/+ and Mmp-19-/- mice, 
respectively (Fig. 2D). Therefore, a significant increase of tumor invasion was observed 
in the absence of host Mmp-19.   
This tumor promoting effect observed in absence of Mmp-19 was not related to a 
modification of tumor cell proliferation rate as assessed by BrdU incorporation. Indeed, 
quantitative assessment performed by computer-assisted image analysis revealed that 
the percentage of proliferating cells was similar in both genotypes, 14 and 21 days after 
tumor transplantation (Fig. 3). Furthermore, TUNEL stainings for apoptotic cells 
indicated that the extent of apoptosis was identical and always low in cancer cell layers 
as well as in stromal strands of transplants resected from WT mice and Mmp-19-/- mice 
(data not shown).  
 
Mmp-19 is produced by host stromal cells  
As a first step in determining the cellular source of Mmp-19, in situ 
hybridization was performed on tumors transplanted into Mmp-19 proficient and 
deficient mice. Hybridization signals for Mmp-19 mRNAs were found in the stroma of 
WT mice (Fig. 4A), but not in that of KO mice (Fig. 4C). No positive signal was 
detected after treatment with sense riboprobe used as negative controls (Fig. 4B). 
Immunohistochemical staining of tumor transplants confirmed the stromal production of 
Mmp-19 (Fig. 5A). This protease was produced by mesenchymal cells (Fig. 5A), but not 
by inflammatory cells positive for CD11b staining (Fig. 5C). Interestingly, Mmp-19 




(data not shown). In contrast, Mmp-19 staining was detected in large vascular structures 
present deeply in the host tissue, below tumor transplants (Fig. 5B). These vessels were 
positive for α-smooth muscle actin and correspond to quiescent mature vessels.  
Lack of Mmp-19 increased angiogenesis in Matrigel plug assay 
To further investigate the impact of Mmp-19 deficiency on angiogenesis in vivo 
and to determine whether the angiogenic response was dependent upon the matrix 
encountered by endothelial cells during their migration, the Matrigel plug assay was 
applied to mutant mice. Matrigel supplemented with bFGF was sub-cutaneously 
injected into the abdomen of wild type and mutant mice (n = 8) and harvested after 7 
days. Quantitative analysis of angiogenesis was performed by measuring haemoglobin 
content in implants giving quantitative information on functional vessels. In accordance 
to results obtained in transplantation chamber assay, the angiogenic response in Mmp-
19 deficient mice was 6-fold increased as compared to that detected in wild type mice 
(Fig. 6) (P< 0.05) and was therefore independent on the type of matrix used (type I 





The analysis of cancer susceptibility in individual Mmp-null mice is of growing 
interest after the failure of synthetic MMP inhibitors in clinical trials and the finding of 
multiple and even opposite roles of MMPs in tumor progression. We describe here that 
in contrast to most MMP deficiencies described up to now in mice, the angiogenic 
response was accelerated and tumor invasion was increased in Mmp-19-deficient mice. 
This was evidenced by (i) an accelerated vascularization and a higher degree of tumor 
invasion after malignant keratinocyte transplantation and (ii) an increased 
vascularization in bFGF treated matrigel implants in Mmp-19-/- mice.  
The time course of malignant growth begins with an early onset of stromal 
activation and infiltration of inflammatory cells and endothelial cells. These key events 
can be mimicked in the transplantation system used here which is a highly sensitive tool 
to inspect kinetics of early steps of host stromal response to tumor signals (34, 35). By 
applying this system to Mmp-19-/- mice, it appears that the angiogenic response was 
affected by lack of host Mmp-19. Surprisingly, endothelial cell recruitment was 
significantly increased 14 days after transplantation, leading to an acceleration of tumor 
vascularization. Consequently, tumor invasion was increased in Mmp-19-deficient mice, 
21 days after tumor transplantation. These findings indicate that Mmp-19 is a negative 
regulator of early steps of cancer angiogenesis and invasion.  
By in situ hybridization and immunohistochemical analysis, we demonstrate that 
mesenchymal cells produce Mmp-19, while CD11b-positive inflammatory cells and 
malignant keratinocytes do not express it. Accordingly, MMP-19 mRNA expression 
and pro-MMP-19 production by human fibroblasts have been detected in vivo in dermal 




sprouting endothelial cells of neo-formed capillaries. This observation fits with our 
previous observation that Mmp-19 is not required for ex vivo endothelial cell migration 
in a collagen gel in the aortic ring assay (24). According to the report of Kolb C et al. 
(25), Mmp-19 is associated with αSMA positive large vessels deeply embedded in the 
host tissue.  
Taking into account its in vitro substrates (laminin-1, laminin-5, type IV collagen, 
fibronectin, tenascin-C or nidogen), MMP-19 might play a key role in matrix 
degradation and tissue remodeling (19, 20, 37). A recent in vitro study suggests that 
through its capacity to cleave nidogen, Mmp-19 could control formation of capillary 
structures on matrigel by cultured endothelial cells (38). However, the ex vivo 
endothelial cell sprouting from mouse aortic rings in a three dimensional matrix was not 
affected by Mmp-19 deficiency (24). Therefore, the accelerated angiogenic response 
observed in vivo in the transplantation system could not be ascribed to a modified 
ability of endothelial cells to migrate or differentiate into capillary-like structures in a 
pure collagen matrix, in the absence of Mmp-19. Interestingly, the accelerated 
recruitment of endothelial cells in vivo was observed both in transplantation system 
using type I collagen and in Matrigel plug assay suggesting that this effect of Mmp-19 
on angiogenesis was not dependent upon the matrix used.  
The identification of novel non matrix substrates for MMPs has extended MMP 
functions beyond their classical role in ECM disruption (4, 11). The recent finding that 
Mmp19 cleaves in vitro IGFBP-3 (39) suggests that it could control the activity of 
insulin-like growth factors and thereby regulate cancer cell growth. However, in our 
system, tumor cell proliferation was not affected by Mmp-19 deficiency. Similarly, 




noting that proteolytic processing of some bioactive molecules such as growth factors 
and/or cytokines/chemokines could also indirectly contribute to micro-environment 
modifications promoting or inhibiting endothelial cell recruitment during angiogenesis 
onset. The assumption that MMPs are in general pro-angiogenic has been challenged by 
the finding that some of them could suppress neovascularization by generating 
angiogenic inhibitors (40). In this context, Mmp-19 could exert its anti-angiogenic 
effect through inactivation of angiogenic/chemotactic factors or production/maturation 
of angiogenic inhibitors. In addition, Mmp-19 production in large quiescent host vessels 
present below tumor transplants, but not in growing capillaries suggests a yet unknown 
functional role of this protease in maintenance of blood vessel stability. Its absence 
could destabilize endothelial cell-mural cell interactions, thereby initiating active 
sprouting events and endothelial cell migration. This hypothesis could explain the 
transient effect of Mmp-19 deficiency at angiogenesis onset.  
The present results do not negate the possibility that Mmp-19 might have dual 
functions during cancer progression. In a model of methylcholanthrene-induced 
chemical carcinogenesis, we previously showed that Mmp-19-/- mice develop less 
fibrosarcomas and with a longer latency period than wild-type littermates (24). These 
apparently paradoxical results may reflect different roles of Mmp-19 in the evolution of 
various cancer types (carcinoma versus fibrosarcoma), as well as throughout different 
steps of cancer progression. The down-regulation and disappearance of MMP-19 
production observed during neoplastic progression in breast and skin carcinomas (21-
23) are consistent with our data demonstrating a control of early steps of skin carcinoma 
evolution by Mmp-19. Altogether these data based on clinical and experimental studies 
suggest that MMP-19 negatively regulates early stages of tumor cell invasion, but 




Temporal differences in effect of proteases on tumor growth and conversion to 
aggressive tumors have also been reported for Mmp-9 (41) and Mmp-11 (42). 
By applying the same transplantation chamber assay into different single or double 
Mmp-deficient mice (43), we previously reported that tumor invasion and angiogenesis 
were both impaired by the combined deficiency in Mmp-2 and Mmp-9 demonstrating 
that concomitant production of gelatinases is required for tumor invasion and 
vascularization. Therefore, although Mmp-2 and Mmp-9 are viewed as positive 
regulators of tumor angiogenesis (4, 44-46), Mmp-19 could function in an opposite 
manner, slowing-down the angiogenic process. These unexpected data are in 
accordance with the emerging anti-tumor properties of some MMPs. In this context, 
skin tumor susceptibility was increased in mice deficient for Mmp-8 (47) or Mmp-3 
(48). Furthermore, our results support the view that MMPs act as sophisticated 
modulators rather than simple inducers or suppressors and highlight the functional 
complexity of MMP family during cancer progression. Some MMPs appear to have 
dual role in cancer progression by promoting angiogenesis and generating angiogenesis 
inhibitors (6). For instance, although MMP-7 and MMP-9 are both able to generate 
angiostatin (40), MMP-7 facilitates tumor progression in mouse models (49) and MMP-
9 promotes tumor angiogenesis (43-46). Increased expression of some MMPs may both 
confer increased tumor cell invasiveness and paradoxically, lead to production of 
molecules that limit tumor growth. Altogether, these data point out the need to 
determine both spatial and temporal significance of individual MMP during cancer 
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Legends of figures: 
Figure 1. A: Histological analysis of tumor transplants: Immunofluorescence 
labeling of malignant keratinocytes and vessels in tumors transplanted into Mmp-19+/+ 
or Mmp-19-/- mice observed after 14 (D14) or 21 (D21) days. Malignant cells (anti-
keratin Ab in green) and vessels (anti-collagen type IV Ab in red) are visualized. The 
dotted line delineates the front of endothelial cell migration. Scores and morphometric 
parameter (d) used to quantify tumor invasion and angiogenesis are indicated (original 
magnification x200). B-C: Semi-quantitative evaluation of tumor vascularization in 
Mmp-19+/+ (black) or Mmp-19-/- mice (white). Tumors were scored as illustrated in 
panel A and in Materials and Methods. n = number of animals per group. D: 
Quantification of tumor vascularization in tumors transplanted for 14 days in Mmp-
19+/+ (black) or Mmp-19-/- (white) mice. “d” = distance separating tumor cell layer 
from the front of migrating blood vessels as defined in panel A (see Materials and 
Methods) (** P≤0.01, Mann-Whitney test) (n = 8). k: malignant keratinocytes; c: 
collagen gel; h: host tissue. 
Figure 2. Quantification of tumor vascularization and invasion in tumor transplants 
based on computer-assisted image analysis. A: Image processing of a typical transplant 
section. Malignant keratinocytes (in green) and vessels (in red) (original image) were 
immunostained according to the procedure described in Materials and Methods. Images 
are binarized with extraction of vessels (Vascularization) or of tumor cells (Invasion). 
Tumor vascularization and tumor invasion were determined by using a grid obtained by 
successive dilatation of the tumor upper border. B-D: determination of vessel density 
(“normalized density of endothelial cells”) (B) and tumor cell density (“normalized 




tumor layer. The maximal distance of tumor cell invasion corresponds to tumor 
thickness (D). Malignant keratinocytes were transplanted into Mmp-19+/+ (WT) and 
Mmp-19-/- (KO) mice for 14 days (D14) or 21 days (D21). 
Figure 3. BrdU immunostaining of tumor transplants. Malignant keratinocytes 
were transplanted for 14 days (D14) (A) or 21 days (D21) (B) into Mmp-19+/+ (black) 
or Mmp-19-/- (white) mice. Before sacrifice, mice were injected with BrdU and 
immunostaining was performed on tumor sections. The percentage of positive cells was 
determined by a computer-assisted method described in Material and Methods. 
Figure 4. In situ hybridization of tumor transplants. Sections of malignant 
keratinocytes transplanted into Mmp-19+/+ (A, B) and Mmp-19-/- (C) mice for 21 days 
were hybridized with 35S-labeled anti-sense Mmp-19 riboprobe (A, C) or sense Mmp-19 
riboprobe (B) used as negative control. Bright fields (left) and dark fields (right) images 
were both captured. Stromal cells in host tissue (h), but not malignant keratinocytes (k) 
were positively stained for Mmp-19 mRNAs (original magnification x100). 
Figure 5. Immunostaining of tumors transplanted into wild type mice. Sections are 
counterstained with bisbenzimide (blue staining). Host stromal cells are positive for 
Mmp-19 immunostaining (in green) (original magnification x200) (A). Double 
immunostainings reveal that Mmp-19 (in red) is not present in newly formed vessels in 
collagen matrix, but is associated to vascular structures stained with α-smooth muscle 
actin (α-SMA) antibody (in green) and localized deeply in host tissue (original 
magnification x400) (B). Mmp-19 (in green) does not co-localize with CD11b-positive 
inflammatory cells (in red) (original magnification x400) (C). Higher magnification is 




Figure 6. Increased vascularization in Matrigel Plug containing bFGF and 
implanted in Mmp-19-/- mice. Functional vascularization was quantified by measuring 
haemoglobin concentration in Matrigel plug implanted into Mmp-19+/+ and Mmp-19-/- 
mice. * P≤ 0.05. 
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